Expression of programmed cell death-1 on neuroblastoma cells in TH-MYCN transgenic mice

[1]  W. Furman.  Monoclonal Antibody Therapies for High Risk Neuroblastoma , 2021, Biologics : targets & therapy.

[2]  M. Podestà,et al.  Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future , 2021, Vaccines.

[3]  M. Cragg,et al.  Immune characterization of pre-clinical murine models of neuroblastoma , 2020, Scientific Reports.

[4]  G. Henze,et al.  Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma , 2020, Journal for immunotherapy of cancer.

[5]  Rachel A. Kudgus,et al.  Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. , 2020, The Lancet. Oncology.

[6]  G. Gao,et al.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy , 2020, Proceedings of the National Academy of Sciences.

[7]  S. Beers,et al.  PD-1/PD-L1 blockade in paediatric cancers: What does the future hold? , 2019, Cancer letters.

[8]  Brett Kahr.  Tissues , 2008, On Practising Therapy at 1.45 A.M..

[9]  Y. Yonemitsu,et al.  Natural antibody against neuroblastoma of TH-MYCN transgenic mice does not correlate with spontaneous regression. , 2018, Biochemical and biophysical research communications.

[10]  H. Yao,et al.  Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy , 2018, Front. Immunol..

[11]  A. Dicker,et al.  Blockade of Tumor-Expressed PD-1 promotes lung cancer growth , 2017, Oncoimmunology.

[12]  B. Zhang,et al.  Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 , 2017, Hepatology.

[13]  P. Sorensen,et al.  Assessment of programmed death‐ligand 1 expression and tumor‐associated immune cells in pediatric cancer tissues , 2017, Cancer.

[14]  P. Zage,et al.  Overview and recent advances in the treatment of neuroblastoma , 2017, Expert review of anticancer therapy.

[15]  J. Nuchtern,et al.  Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies. , 2016, Seminars in pediatric surgery.

[16]  R. Kiessling,et al.  Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade , 2016, Oncoimmunology.

[17]  R. Hanada,et al.  Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers , 2016, Pediatric blood & cancer.

[18]  R. Kiessling,et al.  Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma , 2016, Clinical Cancer Research.

[19]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[20]  G. Adema,et al.  Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents , 2015, Cancer Immunology, Immunotherapy.

[21]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  William A Weiss,et al.  Neuroblastoma and MYCN. , 2013, Cold Spring Harbor perspectives in medicine.

[23]  S. Nilsson,et al.  Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma , 2012, PloS one.

[24]  F. Berthold,et al.  Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Zhigang Tian,et al.  Defining the critical hurdles in cancer immunotherapy , 2011, Journal of Translational Medicine.

[26]  R. Stallings,et al.  miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs , 2011, PloS one.

[27]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[28]  A. Nakagawara,et al.  A Simple PCR Method for Rapid Genotype Analysis of the TH-MYCN Transgenic Mouse , 2009, PloS one.

[29]  Michelle Collazo,et al.  Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.

[30]  M. Jackson,et al.  Histological profile of tumours from MYCN transgenic mice , 2008, Journal of Clinical Pathology.

[31]  G. Freeman,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[32]  A. Peaston,et al.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Bibby,et al.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. , 2004, European journal of cancer.

[34]  G. Trinchieri,et al.  Mouse Strain Differences in Plasmacytoid Dendritic Cell Frequency and Function Revealed by a Novel Monoclonal Antibody , 2003, The Journal of Immunology.

[35]  C. Ardavı́n.  Origin, precursors and differentiation of mouse dendritic cells , 2003, Nature Reviews Immunology.

[36]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.